Fundraising Fox
/Companies
Sign in

FoRx Therapeutics

Basel, CH · Founded 2019 · 35 employees on LinkedIn · 4 known investors

Find your way into FoRx Therapeutics

Sign up to see every warm intro you have to FoRx Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the FoRx Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

FoRx Therapeutics is a biotechnology company focused on oncology drug discovery and clinical development, targeting the DNA Damage Response (DDR) network with small molecule inhibitors. Its work centers on cancer therapeutics developed by a team with pharma and biotech backgrounds.

BiotechDeep TechHealthtech

Founders & leadership

TBTarig Bashir
Tarig BashirChief Executive Officer (CEO)
JWJens Würthner
Jens WürthnerChief Medical Officer (CMO)
FZFrank Zenke
Frank ZenkeChief Scientific Officer (CSO)Frank Zenke is Chief Scientific Officer at FoRx Therapeutics, a biotechnology company developing oncology therapeutics targeting the DNA Damage Response network. He brings over 20 years of experience in drug discovery and development focused on DDR-targeting strategies.

Investors · 4

Novartis Venture Fundlisted by Novartis Venture FundBasel · $5M – $25M

How we know: Novartis Venture Fund's portfolio page · a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · the VCSheet dataset · Not right? Tell us

Omega FundsreportedBoston

How we know: a partner's Signal profile · Not right? Tell us

Funding

SEC filings, press & company announcements

$50M disclosed across 1 of 2 rounds · 2020–2025

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Board of Directors - FoRx Therapeuticsforxtherapeutics.com · Feb 2026Pipeline - FoRx Therapeuticsforxtherapeutics.com · Feb 2026FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor - FoRx Therapeuticsforxtherapeutics.com · Dec 2025Swiss BioTech FoRx Therapeutics closes €42 million for next-generation DNA repair cancer therapy | EU-Startupseu-startups.com · Dec 2025FoRx Therapeutics AG Raises EUR 10 Million Seed Round First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer - FoRx Therapeuticsforxtherapeutics.com · Apr 2020

Frequently asked questions

What does FoRx Therapeutics do?
FoRx Therapeutics is a biotechnology company focused on oncology drug discovery and clinical development, targeting the DNA Damage Response (DDR) network with small molecule inhibitors. Its work centers on cancer therapeutics developed by a team with pharma and biotech backgrounds.
Who are FoRx Therapeutics's investors?
FoRx Therapeutics's investors include M Ventures, Novartis Venture Fund, Pfizer Venture Investments, Omega Funds.
How much funding has FoRx Therapeutics raised?
FoRx Therapeutics has disclosed $50M raised across 1 of its 2 known rounds.
Where is FoRx Therapeutics headquartered?
FoRx Therapeutics is headquartered in Basel, CH.